Progenics Plummets on Rejection of New Use of Relistor Drug
Progenics Pharmaceuticals Inc. (PGNX) fell the most in more than four years after failing to gain U.S. approval to expand use of its constipation medicine Relistor licensed to Salix Pharmaceuticals Ltd. (SLXP)
Progenics plunged 44 percent to $6.09 at 9:51 a.m., after declining to $5.94 in its biggest intraday drop since March 2008. Salix decreased 12 percent to $46.87. The U.S. Food and Drug Administration asked for more data about the treatment for opioid-induced constipation in adult patients with chronic, non- cancer pain, the companies said in a statement July 27.
Relistor was approved in 2008 for opioid-induced constipation in patients with advanced illnesses who haven’t responded to laxative therapy. Progenics, based in Tarrytown, New York, licensed Relistor to Raleigh, North Carolina-based Salix worldwide except for Japan in February 2011.
The companies intend to request a meeting with the FDA to better understand why wider use of Relistor was rejected. The meeting may be scheduled in 45 to 60 days, Michael Freeman, a spokesman for Salix, said in an e-mail today.
Salix will no longer add an additional 160 primary-care sales representatives later this year and plans to update its 2012 earnings forecast when it releases second-quarter results on Aug. 8, Freeman said.
The FDA in April extended its review of the application for wider use of Relistor. The agency didn’t ask for new studies at the time, the companies said in a statement at the time.
Opioids relieve pain by working with receptors in the brain and spinal cord and also interact with receptors in the gastrointestinal tract and can cause debilitating constipation, according to Salix. Subcutaneous Relistor injections decrease opioids’ constipating effects without affecting their ability to relieve pain.
To contact the reporter on this story: Anna Edney in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.